Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 1999

View Archived Issues

Transkaryotic Therapies: Q1 1999 highlights

Connetics: Q1 1999 highlights

Allelix: Q2 1999 highlights

LXR Biotechnology receives disappointing preliminary preclinical results with Elirex

Micro Therapeutics begins brain tumor trial for Embolyx

Sheffield's metered-dose inhaler in clinical trials in Europe

Medtronic's urinary control device approved by FDA

Scotia: Annual Report 1998

Kissei designs new series with potent and selective bronchodilating effects

Inhibitors of NOS described by Pfizer

Novel quinolones with antitumor/antibacterial effects synthesized in China

Chinese investigators develop new antimicrobial agents

Sepracor's (R,R)-formoterol demonstrates fast-onset, long-lasting effects on FEV1 in phase IIa study

Design and evaluation of prodrugs of MAO-A inhibitors presented by Astra Arcus

Spotlight on IL-5 as a target for the treatment of inflammatory diseases

Preliminary evidence of efficacy and safety of N-acetylcysteine in AD

Improvement in spasticity noted with small doses of Zanaflex

SciClone awarded Cystic Fibrosis Foundation grant for CPX

Lamotrigine effective in HIV-associated painful sensory polyneuropathy

Harvard Scientific considers changing name

U.S. patent issued to NitroMed, providing protection for MED/FSAD treatment program

Canadian launch for world's first Lyme disease vaccine

Tryptamine analogues as potent and selective human 5-HT2A antagonists

Safety and immunogenicity of TA-GW demonstrated in phase IIa study

Guilford's new PARP inhibitors potentially useful for wide variety of disorders

Japanese marketing approval granted for AIDS wasting treatment

Safety and efficacy of riluzole examined in pilot study in early, untreated PD

First E.U. approval of Atridox for periodontal disease

SunPharm: year-end 1998 highlights

NDA for Natrecor not approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...